Harbron, Chris

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 262

A flexible unified approach to the analysis of pre‐clinical combination studies

Harbron, C. (2010) · Statistics in Medicine

Statistical Methods in Clinical TrialsOptimal Experimental Design Methods

Cited by 31

Investigation of the robustness of two models for assessing synergy in pre‐clinical drug combination studies

Whitehead, A., Su, T., Thygesen, H., Sperrin, M., & Harbron, C. (2013) · Pharmaceutical Statistics

Statistical Methods in Clinical TrialsOptimal Experimental Design Methods

Cited by 6